Last reviewed · How we verify
LY01011
LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | LY01011 |
|---|---|
| Also known as | recombinant anti-RANKL human monoclonal antibody injection, subcutaneous injection of 120 mg (1.7 ml) |
| Sponsor | Luye Pharma Group Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
LY01011 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Hypoglycemia
Key clinical trials
- Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors (PHASE3)
- A Study to Evaluate LY01011 and Xgeva® in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY01011 CI brief — competitive landscape report
- LY01011 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI